<DOC>
	<DOCNO>NCT00940095</DOCNO>
	<brief_summary>The aim study demonstrate clazosentan , administer continuous intravenous infusion either 5 mg/h 15 mg/h Day 14 post aneurysmal subarachnoid hemorrhage ( aSAH ) , reduce incidence cerebral vasospasm-related morbidity all-cause mortality within 6 week post-aSAH treat endovascular coiling . The primary endpoint study occurrence cerebral vasospasm-related morbidity , mortality all-causes within 6 week post-aSAH , define least one following : 1 . Death ( cause ) . 2 . New cerebral infarct ( ) due cerebral vasospasm either primary relevant contributing cause , adjudicate entirely due cause vasospasm . 3 . Delayed ischemic neurological deficit ( DIND ) due cerebral vasospasm either primary relevant contributing cause , adjudicate entirely due cause vasospasm . 4 . Administration valid rescue therapy presence confirm cerebral vasospasm angiography ( DSA CTA ) . An independent Critical Events Committee ( CEC ) adjudicate whether patient meet primary endpoint individual morbidity component .</brief_summary>
	<brief_title>Clazosentan Aneurysmal Subarachnoid Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<criteria>Inclusion Criteria : 1 . Males female age 18 75 year ( inclusive ) . 2 . Patients rupture saccular aneurysm , confirm angiography ( digital subtraction angiography [ DSA ] compute tomography angiography [ CTA ] , investigator 's assessment ) , successfully* secure endovascular coiling . The time aneurysm rupture must know possible estimate reasonable degree certainty . 3 . World Federation Neurological Surgeons ( WFNS ) grade IIV measure prior endovascular coil procedure , worsen grade V postprocedure ( base regular Glasgow Coma Scale [ GCS ] ) ( 1 ) 4 . Patients thick clot ( short axis &lt; 4 mm ) baseline CT scan ( investigator 's assessment ) . 5 . Women childbearing potential must negative serum pregnancy test must use reliable method contraception 12 week follow study drug discontinuation . 6 . Written inform consent participate study must obtain patient legal representative prior initiation studymandated procedure randomization . A successful procedure define procedure end procedure DSA indicate coil complete adequate ( i.e. , 50 % volume aneurysm fill coil material , investigator 's assessment ) patient schedule 2nd procedure rupture aneurysm within 12 week postaSAH . 1 . Patients must evaluable WFNS grade prior endovascular coil procedure . Patients assess WFNS post procedure due requirement uninterrupted sedation ( e.g. , high unstable intracranial pressure [ ICP ] ) may include study provide CT scan perform least 12 hour postprocedure , prior randomization , rule large procedurerelated infarct . Exclusion Criteria : 1. subarachnoid hemorrhage ( SAH ) due cause saccular aneurysm . 2. giant aneurysm ( height width &gt; = 25 mm ) . 3. intraventricular intracerebral blood , absence subarachnoid blood , clot thin ( short axis &lt; 4 mm ) . 4. cerebral vasospasm angiography ( investigator 's assessment ) prior endovascular coiling ( intraprocedural cerebral vasospasm exclusion criterion ) . 5. major complication endovascular coil procedure , massive intracranial bleeding , intracranial thromboembolism , coil migration , aneurysm perforation rupture , arterial dissection , major arterial occlusion , large territorial cerebral infarct define involve &gt; 1/3 vascular territory , new major neurological deficit postprocedure ( e.g. , hemiplegia aphasia last &gt; = 12 hour postaneurysm coil ) * . 6. current rupture aneurysm previously secure ( successfully ) clip . 7. coil material use , approve local health authority . 8. use liquid embolism aneurysmal treatment flow divert device . 9. several aneurysm among ruptured one identify certainty secure coiling procedure . 10. endofprocedure DSA . 11. another securing procedure plan aneurysm randomization Week 12 postaSAH . 12. study drug start &gt; 56 hour aneurysm rupture . 13. know , time screening , certain followup , protocolmandated imaging assessment feasible . 14. hypotension ( systolic blood pressure &lt; = 90 mmHg ) refractory treatment . 15. aspiration pneumonia . 16. pulmonary edema severe cardiac failure require inotropic support time randomization . 17. severe unstable concomitant condition disease ( e.g. , know significant neurological deficit , cancer , hematological , coronary disease , psychiatric disorder ) , would affect assessment safety efficacy study drug ( investigator 's opinion ) . 18. significant kidney disease define plasma creatinine &gt; = 2.5 mg/dL ( 221 micromol/l ) and/or liver disease define total bilirubin &gt; 2fold Upper Limit Normal measure local laboratory , and/or know diagnosis clinical suspicion liver cirrhosis . 19. infusion i.v . nimodipine i.v . nicardipine must drug discontinue least 4 hour prior initiation study treatment . 20. infusion i.v . fasudil within 24hour period precede plan start study drug initiation . 21. start statins less 2 week prior admission must discontinue prior study drug initiation . 22. infusion cyclosporin A calcineurin inhibitor ( e.g. , tacrolimus ) , patient know time randomization medication start study drug infusion period . 23. intake investigational product include investigational coil material within 28 day prior randomization already participate current study CONSCIOUS2 ( AC054301 ) . 24. unlikely event comply protocol ( e.g. , unable return followup visit ) . 25. known hypersensitivity endothelin receptor antagonists.26.current alcohol drug abuse/dependence . `` Large territorial infarct '' refers infarct detect endovascular coiling procedure immediately postprocedure ( i.e. , CT perform suspicion cerebral infarct complication ) . This imply wait 2448 hour postprocedure perform protocolmandated CT scan order randomize patient . Evaluation new major neurological deficit postprocedure imply reversal sedation performance GCS examination ( verbal score intubate patient may extrapolate eyeopening motor score use predefined value ) . If new major neurological deficit improve within 12 hour coil procedure , patient include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Aneurysmal</keyword>
	<keyword>Subarachnoid</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>vasospasm</keyword>
	<keyword>clazosentan</keyword>
	<keyword>PIVLAZ</keyword>
	<keyword>Actelion</keyword>
	<keyword>surgical clipping</keyword>
</DOC>